Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury (Hour 2) 40 min · 24 Sep 2026 · Rahimi & Grote Show

Cubs squander chance to clinch playoff berth in losing to Marlins, 3-2 (Hour 1) 42 min · 24 Sep 2026 · Rahimi & Grote Show

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury 19 min · 24 Sep 2026 · Rahimi & Grote Show

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

1PM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded05 Jun 2026

Publisheraudiomedica.com ↗

Handlerec:19315651

Show notes

Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer An interview with: Peter Schmid MD PhD, Professor of Cancer Medicine;

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related